{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Time from initiation of therapy until disease progression (\\>25% increase in serum IgM and 500 mg/dL absolute increase).","groups":[{"description":"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.\n\n* Ibrutinib will be administered at a predetermined dose, once daily for 28 days\n* TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment)\n* Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up during cycle 2.\n\nIBRUTINIB: Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days\n\nVenetoclax: Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.","id":"OG000","title":"Ibrutinib and Venetoclax"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"36 Months","title":"Progression Free Survival (PFS) at 36 Months","type":"SECONDARY","unitOfMeasure":"Participants"}